Latest Breaking News On - Neurology neuroimmunology - Page 6 : comparemela.com

Horizon Therapeutics plc: New Analysis of UPLIZNA (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation published in the Annals of Neurology assesses a potential new biomarker for NMOSD attack risk, severity and treatment effects Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis of the pivotal Phase 2/3 N-MOmentum trial for UPLIZNA (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with NMOSD. These data are published in the May issue of Neurology Neuroimmunology Neuroinflammation. UPLIZNA is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.

Quinn dinhRuth venningA neuromyelitis opticaRay gordonNeuroimmunol neuroinflammTina venturaNeuroimmunology neuroinflammationRachel vannProduct communicationsNeurology neuroimmunologyHepatitisb virusProgressive multifocal leukoencephalopathyPrescribing informationNeuromyelitis optica spectrum disorderNeuromyelitis optica spectrumNeurol neuroimmunol